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Translating Treg Therapy in 
Humanized Mice
Susanne A. Hahn* , Iris Bellinghausen , Bettina Trinschek and Christian Becker
Department of Dermatology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany
Regulatory T cells (Treg) control immune cell function as well as non-immunological pro-
cesses. Their far-reaching regulatory activities suggest their functional manipulation as a 
means to sustainably and causally intervene with the course of diseases. Preclinical tools 
and strategies are however needed to further test and develop interventional strategies 
outside the human body. “Humanized” mouse models consisting of mice engrafted with 
human immune cells and tissues provide new tools to analyze human Treg ontogeny, 
immunobiology, and therapy. Here, we summarize the current state of humanized mouse 
models as a means to study human Treg function at the molecular level and to design 
strategies to harness these cells for therapeutic purposes.
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THe eMeRGeNCY OF Treg AS THeRAPeUTiC TARGeT
The notion that T cells can be actively involved in immunological tolerance goes back to the seventies 
of the last century when it was shown that T cells (thymus-derived lymphocytes) are required for 
tolerance induction and could transfer tolerance to naïve recipients (1, 2). Tolerance induction by 
T cells has thereafter been convincingly demonstrated by numerous investigators using a variety 
of experimental systems (3, 4). Despite decades of research, it was not possible to unequivocally 
identify the responsible T cell population. In the 90s, Simon Sakaguchi and colleagues were able 
to prove that a small population of constitutively CD25-expressing CD4+ T cells prevents autoim-
mune disease in mice (5). The discovery of the X chromosome encoded transcription factor Foxp3 
(forkhead box protein 3) (6–9) as a specification and maintenance factor (10, 11) subsequently 
confirmed CD4+CD25+ T cells as a unique thymus-derived lineage. A population of phenotypically 
and functionally similar T cells could also be corroborated in humans (12, 13). Examining their role 
in the murine immune system revealed that regulatory T cells (Treg) – as they had been called in 
foresight – take a central role in immune homeostasis: genetic defects that turn Treg dysfunctional 
result in multiorgan autoimmune disease (14) and their depletion induces autoimmunity (15). The 
investigation of their suppressive activity was greatly helped by major improvements in molecular 
profiling techniques and revealed a number of potential suppressive mechanisms (16). More recently, 
several Treg effector molecules were found to play a role in Treg peripheral expansion and activation 
rather than suppressive activity (17) or contribute to Treg function only under particular conditions 
(18). Moreover, only few mechanisms have been confirmed in mice and man (19–21).
While Treg were initially investigated mainly in regard to their effects on T cells, their far-reaching 
regulatory activity affects the activation, differentiation, and survival of all types of immune cells. 
Although their main role appears to be the prevention of autoimmune reactions their broad immune-
regulatory potential and bystander activation in immune responses affects a wide range of conditions 
such as infection, cancer, transplantation, allergy, and inflammatory diseases, but also responses 
toward foreign antigens, as well as fetal antigens during pregnancy (22–28).
TABLe 1 | Reported Treg alterations in autoimmune diseases.
Disease Source Observations Reference
Multiple 
sclerosis
Blood Normal frequencies, 
decreased suppressive 
function
(53, 64–66)
Cerebral  
spinal fluid
Enhanced frequency, 
memory phenotype
Rheumatoid 
arthritis
Blood Contradictory results on 
frequencies
(67, 68)
CD62+Treg appear 
functionally impaired
Inflamed joint Enhanced frequencies
Type I diabetes Blood Contradictory results on 
frequencies
(69, 70)
Crohn’s 
disease
Blood Contradictory results on 
frequencies
(71, 72)
Enhanced Foxp3+IL-17+ T 
cells
Systemic lupus 
erythematosus
Blood Reduced frequencies 
correlate with enhanced 
disease activity
(51, 73)
Psoriasis Blood Contradictory results (74–76)
Psoriatic 
plaques
Enhanced Foxp3 expression
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Murine and human Treg, like all T cells, consist of numerous 
differentiated subpopulations (29–38). While in some cases, the 
functional properties of subpopulations have been described in 
detail, a systematic assignment of phenotypes and functions is 
missing in both species. Strikingly, beyond their role in immune 
homeostasis and immune cell regulation, specialized Treg sub-
populations also interfere with non-immunological processes 
such as metabolism (39) and wound healing (36, 40, 41). So far, 
the latter populations have so far exclusively been described in 
mice.
To date, the vast majority of data concerning Treg were 
obtained from mouse experiments. The reason for this is the fact 
that human tissue cannot always be investigated. However, human 
Treg studies are also technically limited by the lack of a reliable 
and specific Treg marker molecule (21, 42). Whereas in healthy 
subjects, the main human Treg population in blood can at least be 
approximated as CD45RO+TCR+CD4+CD25highFoxp3+CD127neg 
cells (43), their analysis and isolation remains affected by similarly 
phenotyped non-regulatory T helper cells under conditions of T 
cell activation such as in inflammatory disease (44, 45). Today, the 
most effective, reliable, and objective criteria for the identification 
and quantification of Treg in diagnostic or therapeutic settings is 
in quantitative real-time PCR-based methylation analysis of an 
evolutionarily conserved element within the Foxp3 locus (46, 47). 
This method however only indirectly contributes to Treg isolation 
from human samples due to associated cell destruction.
Their potent and far-reaching regulatory activities have helped 
Treg to become a major subject in virtually all fields of medical 
research. With regard to the lack of a comprehensive under-
standing of human Treg composition and function, a cautionary 
approach to Treg modulation in patients appears to be warranted, 
even more so, as animal models failed to predict effects of Treg 
modulating agents in humans (48). The latter, in particular, has 
made clear that human Treg function as well as Treg targeted 
immune intervention need to be examined more closely. As these 
studies cannot be performed in man, a model organism is required 
in which the function of human cells can be examined outside 
the human body. In recent years, humanized mouse models have 
emerged as a suitable tool to study human Treg function and to 
develop strategies for their therapeutic application.
Treg iN AUTOiMMUNe DiSeASe AND 
CANCeR
The main physiological role of Treg appears to be the prevention 
of autoimmune responses (49) as evidenced by fulminate auto-
immune reactions in their absence (50) (Table 1). In turn, their 
autoprotective activity suggests that autoimmune diseases may 
result from their functional impairment. While their peripheral 
number remains unchanged in the majority of autoimmune 
diseases (51–53), their suppressive function seems to be indeed 
altered (51, 52, 54–56). However, retrospective studies in patients 
are confused with the problem that Treg dysfunctionality can be 
either intrinsic or reflect changes in other immune components 
(57–61). The autoimmune phenotype of scurfy mice, for example, 
results from both Treg dysfunction and an increased population 
of self-reactive T cells emerging from progenitor cells which did 
not properly develop into Treg. Thus, to reveal the functional state 
of Treg and to understand their role and possible effects in disease, 
causes and effects need to be carefully discerned. As shown by 
Trinschek et al. (62), humanized mouse models can help to eluci-
date disease mechanisms by enabling to individually manipulate 
and combine diseased and unaffected Treg from patients and 
healthy donors. It needs to be mentioned that in addition to the 
thymus-derived Treg population non-regulatory CD4+ T cells 
can acquire a similar regulatory function and phenotype outside 
of the thymus, typically under the influence of particular forms of 
inflammation (63). Here, we focus on thymus-derived Treg since 
they are the most widely studied in humanized mice.
Regardless of numerous genetic changes, tumors are primar-
ily the body’s own tissue (77). Their destruction by the immune 
system therefore represents – at least in part – an autoimmune 
response. Since Treg appear to be in part self-reactive (78), it is 
not surprising that increased Treg activity is causally involved in 
tumor-induced tolerance (52, 79). Numerous studies reported 
elevated numbers of Treg in the tumor tissue, lymphoid tis-
sues, and peripheral blood of cancer patients (43, 52, 79–81), 
also the infiltrating of Treg into the tumor site correlates with 
poor prognoses in many tumor types (82). Some mechanisms 
of tumor-associated Treg recruitment and activation have been 
proposed (83–85), but may vary between tumor types and/
or stages. Whereas Treg depletion increases all inflammatory 
responses including antitumor immunity (86), it is effective 
only in early stages of tumor growth (87, 88). Despite its proven 
genuine potential as a strategy to overcome tumor tolerance, 
Treg depletion is not yet a therapeutic option in cancer patients. 
While animal experiments strongly indicate that only a complete 
and selective Treg destruction may affect antitumor immunity, 
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Treg depletion in cancer patients is hampered by inefficient non-
specific depleting agents, which cause unwanted side effects (89). 
On the other hand, current treatment options such as immune 
checkpoint blockade seem to affect the Treg compartment (90). 
Thus, further investigation on the interaction of Treg and tumor 
cells in humans are needed and reagents for effective and selective 
Treg destruction need to be identified.
HUMANiZeD MOUSe MODeLS: 
CHALLeNGeS AND LiMiTATiONS TO 
STUDY HUMAN Treg BiOLOGY
The simplest way to equip mice with human immune cells 
(mainly PBMC) is their intravenous or intraperitoneal injection 
(Figure  1). In order to accept the human graft, the recipients 
need to be immunodeficient and the degree of deficiency strongly 
influences the survival and function of transplanted human cells. 
Initial experiments by McCune and Mosier in severe combined 
immunodeficient (SCID) mice lacking T and B cells revealed that 
human immune cells can survive in mice for several weeks (91, 
92). However, due to the remaining innate immunity and leaki-
ness in adaptive cell development in aged SCID mice, transplanted 
human cells are only transiently accepted. Reduced natural killer 
cell (NK cell) activity in non-obese diabetic (NOD)-SCID mice 
improve engraftment. Profound and lasting impairment of 
adaptive and innate immunity by targeted mutation of the IL-2R 
gamma-chain gene in NOD-SCID IL-2Rγ−/− (NSG) or BALB/c 
recombinase activating gene (Rag)2−/− IL-2Rγ−/− mice eventually 
enable a stable long-term survival of transplanted human cells 
and tissues (93–99).
Upon engraftment of human PBMC into immunodeficient 
mice, a population of human T cells reacts against murine MHC 
molecules, supposedly on murine antigen-presenting cells, result-
ing in T cell-driven lethal xenogeneic graft-versus-host disease 
(GvHD) (92, 94, 100). In contrast to T cells, other transferred 
immune compartments such as myeloid cells, dendritic cells, or 
B cells rapidly vanish or at least become irretrievable. In adult 
NOD-SCID, sublethal irradiation or depletion of innate murine 
immune cells (called “conditioning”) accelerates GvHD onset. In 
contrast, GvHD can be reliably induced in newborn NOD-SCID 
and gamma-chain-deficient recipients without conditioning.
Graft-versus-host disease upon transfer of human PBMC is 
characterized by weight loss (or lack of weight gain in pubs), 
reduced mobility and a total mortality >95% (20). At the tissue 
level, it is accompanied by a massive infiltration of human T cells 
into all mouse organs leading to peribronchial and perivascular 
inflammation and increased mucus production, colitis, skin 
rashes, and increased glutamate pyruvate transaminase (GPT) 
serum levels indicative of hepatitis. When performed in new-
born NOD-SCID mice, GvHD leads to death within 30–90 days, 
depending on the number of transferred PBMCs. Interestingly, 
the number of transferred T cells and their functional state 
influences disease onset: both increased cell numbers and cells 
from autoimmune patients accelerate disease onset (62). While 
increased cell numbers contain more xenoreactive cells, the 
reason for the latter effect is not completely clear. Supposedly, 
disease-mediated alterations in the T cell compartment, cross-
reactivity or increased inflammatory cytokine production may 
act beneficial.
Owing to its simplicity, the xenogeneic GvHD provides a 
robust means to functionally evaluate Treg outside the human 
body (Figure 2): Without further treatment, the limited number 
of Treg transferred within the PBMC do not affect GvHD onset. 
However, transfer of additional Treg in ratios between 4:1 and 
10:1 (PBMC:Tregs) suppresses all GvHD symptoms in a dose-
dependent manner (20, 101). Since the suppressive activity of 
Treg is not antigen specific, either syngenic or allogeneic Treg 
may be used. Treg ratios lower than 10:1 appear ineffective, 
however, allowing to test biologicals with modest Treg-activating 
potential (102).
Differences exist between mouse strains in regard to the 
persistence of Treg-mediated GvHD suppression. While in NOD-
SCID mice, Treg-induced tolerance remains stable for weeks 
(20), it is only transient in NOD-SCIDγc−/− or Rag2γc−/− mice 
(102, 103). Thus, while all three strains can be used to investigate 
human Treg activation in  vivo, a long-term evaluation of the 
functional state is only possible in the later model. Not only Treg 
numbers but also certain biologicals have been shown to selec-
tively increase or repress Treg function in the transfer model (20, 
104–106). Particularly, strong stimuli can prevent the xenogeneic 
response without increasing the number of Treg in PBMC (20). 
Alternatively, Treg can be separately pretreated with modulating 
agents or pathway inhibitors before transfer (107, 108). The latter 
approach is especially helpful in testing compounds which lack 
Treg specificity. Similar to in vitro assays, the GvHD model can 
be used to discern patient-associated functional alterations in 
Treg or T effector cells by combining either cells from patients or 
healthy donors (62).
Without Treg activation, the xenogeneic GvHD cannot be 
prevented. It is however delayed by the transfer of very low cell 
numbers and greatly reduced in MHC class I or class II knock-
out NOD-SCIDγc−/− or Rag2γc−/− mice (100, 109, 110). In this 
manner and by the use of PBMC from patients’ inflammatory 
responses such as allergy-induced inflammation and its regula-
tion by Treg can be studied (102, 111–114). In the same manner, 
the transfer model has been used to analyze the mechanism of 
wound healing, tissue remodeling, and allograft rejection after 
tissue transplantation. Several investigators reported that the 
transfer of Treg prevented the rejection of human skin, islets, 
bronchus, and arterial grafts (96, 115–119). In addition to the 
general effect of Treg on the disease, these models can be used to 
compare differently isolated or expanded Treg populations (28, 
120). So far, almost only total CD4+CD25+ populations have been 
used, followed by approval of disease repression, but without 
looking at their further development and survival.
Since current animal models may not accurately identify can-
cer immunotherapies with clinical potential, reliable preclinical 
tools are needed to test these drugs directly against human can-
cers. Here again, in its simplest form, a humanized mouse tumor 
model can be set up by cotransplantation of human immune 
cells and tumors. The first difficulty in setting up such a model 
consist in the constitutive dependency of primary human tumor 
cells on host growth factors, which greatly limits their ability to 
FiGURe 1 | Humanized mouse models and their potential application in Treg research.
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grow in a different species. Alternatively, long-term established 
tumor cell lines engraft well and are readily available. Depending 
on their origin and methodology of cultivation human tumor cell 
lines can phenocopy primary tumors (121, 122). Their growth 
in immunodeficient mice therefore provides a robust cell line 
model system that potentially predicts patient responses to drugs 
or biologicals (123, 124).
Adding human immune cells either by transplantation of 
immune cells or stem cells, does however, complicates the setting. 
Cotransplantation of human immune cells and allogeneic tumor 
FiGURe 2 | Treg manipulation in the xenogeneic GvHD model. (A) 
Disease symptoms; (B) examples of biologicals with demonstrated Treg 
activating or inactivating activity in the GvHD model; Tcon = conventional 
non-regulatory T cell.
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cell lines creates the need to distinguish between xenogeneic, 
allogeneic, and potential tumor-specific responses. Although 
tumor-specific responses may be selectively followed by MHC 
complex multimers, they will be cross-influenced by strong 
inflammatory xenogeneic and/or allogeneic background activi-
ties. Therefore, a more promising approach consists in a syngeneic 
approach. In a syngeneic setting, CD8+ CTL have been shown to 
effectively combat patient tumor cells in immunodeficient mice 
(125, 126), and such models may help to identify tumor rejection 
antigens and T cell receptors for redirecting immunity to tumors 
in a patient-individualized manner. Although more complicated 
to set up, they may also provide a basis to study the interaction 
between patient-derived Treg and tumor cells and to develop 
reagents for effective and selective Treg impairment.
Another way to humanize mice is to transfer hematopoietic 
stem cells (HSC) either alone or in combination with human 
tissues required in lymphocyte development (Figure  1). Upon 
transfer of HSC into newborn or adult mice, multiple lineages 
of human hematopoietic cells (including T and B cells, plasma-
cytoid cells, myeloid cells, and NK cells) develop, resulting in a 
mixed murine/human CD45+ cells compartment. Even greater 
levels of human cell engraftment are achieved when human fetal 
tissue is cotransplanted. In the BLT (bone marrow/liver/thymus) 
model, human fetal liver and autologous thymus fragments are 
implanted under the renal capsule and HSC cells isolated from 
the same fetal liver are separately transferred to engraft the bone 
marrow.
Whereas in HSC-humanized mice, human T cells populate 
the murine thymus and become H2 restricted, they appear 
to remain HLA restricted in the BLT model (99, 127–129). To 
achieve HLA-restriction in the former, multiple HLA-transgenic 
NSG mice have recently been developed (110, 128, 130–133). 
HSC-based humanized mouse models have also been further 
modified by replacing distinct murine genes with the cor-
responding human alleles using knock-in technology, or the 
transcription activator like effector nuclease (TALEN) technol-
ogy (134, 135). Each human factor improves the development of 
certain human hematopoietic lineages. Administration of human 
IL-15, for example, promotes human NK cell development, while 
human IL-7 enhances the maintenance of immature thymocytes 
(136–138). Similarly, transient expression of human GM-CSF and 
IL-4, macrophage colony-stimulating factor, or erythropoietin 
and IL-3 (SGM3) increase the reconstitution of DC, monocytes/
macrophages, and erythrocytes, respectively (135, 136, 139). In 
membrane-bound human stem cell factor (SCF)-expressing NSG 
mice, the differentiation of immature and mature granulocytes 
including c-Kit+ human mast cells has been described (140).
In stem cell-transplanted humanized mice, the developing 
human T cell compartment includes CD4+CD25+Foxp3+ Treg. 
Interestingly, the transfer of human CD34+ HSC into NSG-
SGM3 mice-expressing transgenes for human SCF, GM-CSF, 
and IL-3 not only led to elevated human myeloid cell frequencies 
in blood, spleen, bone marrow, and liver compared with non-
transgenic NSG recipients, but also to a significant increase in the 
CD4+CD25+Foxp3+ Treg population. Furthermore, the authors 
demonstrated Treg expansion in the periphery and not in the 
thymus as the numbers of CD4+Foxp3+ thymocytes were similar 
in both mouse strains. Human DC subsets capable of regulating 
Treg cell frequencies were suggested as one possible mechanism 
(141, 142). In these models, Treg have been shown to suppress 
polyclonally activated T cell proliferation (141) and can be 
engaged to prevent fibrosis (143).
Unfortunately, like in the transfer models, HSC-humanized 
mice develop GvHD (144–146). Onset of GvHD is not prevented 
by the lack of murine MHC molecules and develops despite the 
presence of human Treg. The development of GvHD in appar-
ently all models limits the experimental window of other immune 
responses and shows that the possible involvement of GvHD, 
even if it cannot be detected based on established parameters 
and its possible influence on other immune responses needs to 
be taken into account.
Considering the many differences between the species, the 
growth and survival of human cells in mice is still a surprising 
find. Many, if not the majority of murine cytokines and growth 
factors, do not bind or insufficiently interact with the respective 
human receptors, and the cells need to adapt to this situation. 
In fact, on closer characterization, proliferating xenoresponsive 
human T cells differentiate into unusual subsets in the xenogeneic 
environment (147, 148). Moreover, phenotypical and functional 
December 2015 | Volume 6 | Article 6236
Hahn et al. Treg Function in Humanized Mice 
Frontiers in Immunology | www.frontiersin.org
analyses of lymphoid lineages in humanized mice >20  weeks 
posthematopoietic stem cell transplantation reveals that CD8+ T 
cells and NK cells exhibited functional impairments (149). These 
observations remind that in humanized mouse models, the mere 
presence of certain cell types cannot be taken for their functional 
property. It is, for example, not known whether the cellular and 
molecular mechanisms that govern the differentiation of the Treg 
population in mice also applies to HSC-based models (150). 
While in the mouse, the composition of the Treg population is 
significantly influenced by commensals, nothing is known in 
the humanized mouse models (151). Thus, in order to translate 
potential Treg therapy into the clinic, the origin, fate, and function 
of Treg in humanized mice must be examined in greater detail.
In summary, in their current state, transfer models provide 
a robust means to evaluate the interaction of Treg with T cells, 
particularly in conjunction with Treg activating or inactivating 
reagents. HSC-based humanized mouse models offer greater 
possibilities but are difficult to set up and less well explored with 
regard to Treg development and function. Observations in SGM3 
mice are encouraging, and further outfitting mice with additional 
human factors may help to overcome existing limitations, which 
might lead to models in where human Treg function and develop-
ment can be studied in a physiological manner.
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